Magnetic signals to improve metabolic health in Type 2 Diabetes

Magnetic Mitohormesis: Effect of Magnetic Signals on Metabolic Adaptions in Type 2 Diabetes

This study is testing a new therapy that uses magnetic signals to see if it can help people with Type 2 Diabetes manage their blood sugar better without needing to exercise.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 40 Years to 75 Years
• Sex: All
• Sponsor: Singapore General Hospital (other)
• Locations: 1 site (Singapore)
• Trial ID: NCT05881200 on ClinicalTrials.gov

What this trial studies

This pilot study investigates the effects of Magnetic Mitohormesis (MM) therapy on glycemic control in individuals with Type 2 Diabetes Mellitus (T2DM). Using a non-invasive BIXEPS machine, MM replicates the metabolic benefits of exercise by applying magnetic fields to the thigh muscles during brief 10-minute sessions. The study aims to provide an alternative method for improving insulin sensitivity and blood glucose levels, particularly for those who may struggle with traditional exercise regimens. Participants will undergo weekly MM sessions to assess its impact on their diabetes management.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 40-75 years with a diagnosis of T2DM for at least 6 months and specific HbA1c and BMI criteria.

Not a fit: Patients with contraindications for magnetic exposure or those with significant health issues that prevent physical activity may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could offer a new, non-invasive treatment option for improving glycemic control in patients with Type 2 Diabetes.

How similar studies have performed: While the concept of using magnetic fields for therapeutic purposes is emerging, this specific approach of Magnetic Mitohormesis is novel and has not been extensively tested in similar studies.

Eligibility criteria

Inclusion Criteria:

1. Age 40-75 years
2. T2DM of at least 6 months duration
3. HbA1c between 7.0% - 10.0% (most recent 3-months prior to enrolment)
4. Body Mass Index (BMI) between 23.0 and 32.5 kg/m2
5. Able to ambulate independently
6. Willing and able to give written informed consent

Exclusion Criteria:

1. Presence of any conditions contraindicated for PEMF exposures (e.g. active electronic implants, pregnancy, pacemakers, implantable defibrillators)
2. Medical advice against physical activity
3. Chest pain when performing physical activity
4. Chest pain at rest
5. BP \> 180/90 mmHg
6. Women who are lactating, pregnant or considering pregnancy
7. Cancer not in remission or receiving active cancer treatment
8. Current participation in another clinical trial
9. Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)
10. Uncontrolled thyroid disease
11. Significant alcohol intake (\> 1 unit per day for women and \> 2 units per day for men)
12. Any factors likely to limit adherence to study protocol (e.g. dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other or family members)
13. Anticipated surgery or changes in diabetes medications during the study duration
14. History of severe hypoglycaemia in the recent 3 months
15. Have used the MM device in the past 3 months
16. Had a recent surgical procedure in the last 6 months, where muscle activation can interfere with the healing response

Where this trial is running

Singapore

• Singapore General Hospital — Singapore, Singapore (RECRUITING)

Study contacts

• Principal investigator: Hong Chang Tan — Singapore General Hospital
• Study coordinator: Aini Vieon Wu

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Exercise, Insulin resistance, Magnetic mitohormesis